367 related articles for article (PubMed ID: 29776658)
1. Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial.
Conway R; O'Neill L; Gallagher P; McCarthy GM; Murphy CC; Veale DJ; Fearon U; Molloy ES
Semin Arthritis Rheum; 2018 Dec; 48(3):523-528. PubMed ID: 29776658
[TBL] [Abstract][Full Text] [Related]
2. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab for the Treatment of Giant Cell Arteritis.
Matza MA; Fernandes AD; Stone JH; Unizony SH
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):893-897. PubMed ID: 32248659
[TBL] [Abstract][Full Text] [Related]
4. Does leflunomide have a role in giant cell arteritis? An open-label study.
Hočevar A; Ješe R; Rotar Ž; Tomšič M
Clin Rheumatol; 2019 Feb; 38(2):291-296. PubMed ID: 30084049
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Giant Cell Arteritis.
Guevara M; Kollipara CS
Curr Rheumatol Rep; 2018 Apr; 20(5):25. PubMed ID: 29611005
[TBL] [Abstract][Full Text] [Related]
7. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.
Wilson JC; Sarsour K; Collinson N; Tuckwell K; Musselman D; Klearman M; Napalkov P; Jick SS; Stone JH; Meier CR
Semin Arthritis Rheum; 2017 Jun; 46(6):819-827. PubMed ID: 28040244
[TBL] [Abstract][Full Text] [Related]
8. Treatment of giant cell arteritis.
González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S
Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796
[TBL] [Abstract][Full Text] [Related]
9. [From pathogenesis of giant cell arteritis to new therapeutic targets].
Samson M; Bonnotte B
Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
[TBL] [Abstract][Full Text] [Related]
10. Management of large-vessel vasculitis.
Salvarani C; Hatemi G
Curr Opin Rheumatol; 2019 Jan; 31(1):25-31. PubMed ID: 30461542
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres.
Loock J; Henes J; Kötter I; Witte T; Lamprecht P; Schirmer M; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S70-6. PubMed ID: 22640650
[TBL] [Abstract][Full Text] [Related]
12. The role of biologics in the treatment of giant cell arteritis.
González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
[TBL] [Abstract][Full Text] [Related]
13. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy.
Nielsen BD; Gormsen LC; Hansen IT; Keller KK; Therkildsen P; Hauge EM
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1119-1128. PubMed ID: 29671039
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
[TBL] [Abstract][Full Text] [Related]
15. Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry.
Alibaz-Öner F; Kelesoglu B; Balci MA; Yardimci GK; Armağan B; Kiliç L; Karakaş Ö; Erden A; Yasar Bilge S; Kardaş RC; Küçük H; Zengin O; Tasci M; Kocaer SB; Yavuz S; Dogru A; Şahin M; Bayindir O; Sevik G; Ertürk Z; Alpay-Kanitez N; Gogebakan H; Tezcan ME; Oksuz MF; Cefle A; Kucuksahin O; Yazici A; Kasapoglu E; Bes C; Unal AU; Dalkiliç E; Yildirim Çetin G; Aksu K; Keser G; Onen F; Çobankara V; Kisacik B; Onat AM; Öztürk MA; Kaşifoğlu T; Omma A; Karadag O; Ates A; Direskeneli H
Clin Exp Rheumatol; 2024 Apr; 42(4):816-821. PubMed ID: 37976117
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging diagnosis tools and therapeutics for giant cell arteritis.
González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients.
Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; De Miguel E; Prieto-Peña D; González-Gay MÁ; Hernández JL; Blanco R;
Semin Arthritis Rheum; 2021 Apr; 51(2):387-394. PubMed ID: 33607384
[TBL] [Abstract][Full Text] [Related]
19. [Management of polymyalgia rheumatica and large vessel vasculitis].
Hellmich B
Internist (Berl); 2016 Nov; 57(11):1069-1078. PubMed ID: 27631531
[TBL] [Abstract][Full Text] [Related]
20. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
